Clinical trials determine the safety and efficacy of cancer therapeutics and pave the way to approval by the U.S. Food and Drug Administration. Previous research has proven that racial and ethnic minorities are significantly underrepresented in clinical trials. Read more . . .
A simulated pancreatic cancer clinical trial screening process showed that Black patients were significantly more likely than white patients to be excluded from clinical trials for a wide range of eligibility criteria, according to results presented at the virtual 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held October 6-8, 2021.